Anti-CD38-SAP [IT-96]

[anti-mouse CD38]-streptavidin-saporin

SKU: IT-96 Category: Quantity: Individual 25 ug, Individual 100 ug, Individual 250 ug, Individual 1 mg, Kit w/controls 25 ug, Kit w/controls 100 ug, Kit w/controls 250 ug | Antibody Type: Monoclonal | Host: rat | Reactivity: mouse | Conjugate: streptavidin-saporin | Usage: eliminates cells, retrograde transport |

CD38 is a 42 kD glycoprotein, also known as T10. It is an ADP-ribosyl hydrolase, expressed on B cells, NK cells, subset of T cells, brain, muscle, and kidney. In the mouse, CD38 expression is downregulated on mouse germinal center B cells and plasma cells, whereas this is not the case for humans. By functioning as both a cyclase and a hydrolase, CD38 mediates lymphocyte activation, as well as adhesion and the metabolism of cADPR and NAADP. CD31 is the ligand of CD38.

Anti-CD38-SAP is a bonded conjugate of a rat monoclonal antibody to mouse CD38 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.

Anti-CD38-SAP eliminates cells expressing mouse CD38 (T10).

Anti-CD38-SAP is available individually (Cat. #IT-96) or as a kit (Cat. #KIT-96) which includes Anti-CD38-SAP and BIgG-SAP Rat (Cat. #IT-73).

keywords: CD38, saporin, SAP, T10, ADP-ribosyl hydrolase, B cells, NK cells, lymphocytes, lymphocyte activation, cADPR, NAADP, CD31, targeted toxin, immunotoxin, ribosome-inactivating protein, monoclonal antibody

View Data Sheet

Development of chemically induced choroidal injury models for the study and treatment of AMD

Han I, Pandala N, Haefeli L, Lang MJ, Stone EM, Mullins RF, Tucker BA (2024) Development of chemically induced choroidal injury models for the study and treatment of AMD. ARVO Annual Meeting 65(7):5382.

Objective: To describe the development of Age-Related Macular Degeneration (AMD) models through the targeted injury of choroidal cells in the eye.

Summary: Anti-CD38-SAP (BETA-016) and Anti-CD105-SAP (IT-80) were utilized to selectively lesion choroidal cells in the eyes of mice, creating an AMD model. Both agents demonstrated localized effects with no observed systemic toxicity at the administered doses, contrasting with the broader toxicity seen with Sodium Iodate, another lesioning agent examined.

Usage: Different doses of Anti-CD38-SAP and Anti-CD105-SAP (0.05, 0.25, and 0.5 mg/ml; 10 μL/eye) were injected suprachoroidally into the eyes of mice to induce the desired choroidal cell lesions.

Related Products: Anti-CD38-SAP Kit (Cat. #BETA-016), Anti-CD105-SAP (Cat. #IT-80)

browse all references for this product | back to top

browse this product category | browse all products | back to top

browse all articles | back to top

browse all videos | back to top

Cytotoxicity Assay for Targeted Toxins in vitro

Concentration Calculation Explained: Convert molarity to mg/ml and mg/ml to molarity

Preparing and Interpreting Cytotoxicity Data in vitro

browse all protocols and calculators | back to top

Shopping Cart
Scroll to Top